Page last updated: 2024-11-08

bromochloroacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

bromochloroacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by bromine while a second is replaced by chlorine. A low-melting (27.5-31.5degreeC), hygroscopic crystalline solid, it can be formed during the disinfection (by chlorination) of water that contains bromide ions and organic matter, so can occur in drinking water as a byproduct of the disinfection process. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID542762
CHEMBL ID504842
CHEBI ID64206
SCHEMBL ID135012
MeSH IDM0261904

Synonyms (49)

Synonym
keratins
NCGC00091488-01
5589-96-8
bromochloroacetic acid
acetic acid, bromochloro-
chlorobromoacetic acid
bromochloroacetic acid, 97%
bromo(chloro)acetic acid
bromochloracetic acid
2-bromo-2-chloroacetic acid
CHEMBL504842
chebi:64206 ,
acetic acid, 2-bromo-2-chloro-
NCGC00091488-02
C19212
68238-35-7
LMFA01090146
2-bromo-2-chloroethanoic acid
NCGC00258448-01
tox21_200894
dtxsid4024642 ,
cas-5589-96-8
dtxcid604642
69430-36-0
hsdb 7619
unii-al8mz37y51
ccris 8228
al8mz37y51 ,
AKOS016010266
FT-0623228
brch(cl)co2h
bromochloroethanoic acid
brch(cl)cooh
chlorobromoacetic acid [hsdb]
bromochloroacetic acid [iarc]
SCHEMBL135012
bromochloroaceticacid
GEHJBWKLJVFKPS-UHFFFAOYSA-N
mfcd00143872
bromochloroacetic acid, analytical standard
bromochloroacetic acid 1000 microg/ml in methyl-tert-butyl ether
bcaa
FT-0627572
Q27133122
E78199
FT-0627573
BS-52910
2-bromo-2-chloroaceticacid
keratin from wool,

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Therefore, these preliminary findings suggest that orally or topically administered 1,25-(OH)2-D3 may be a safe and effective alternative therapy for the treatment of psoriasis."( A novel approach for the evaluation and treatment of psoriasis. Oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy for psoriasis.
Donovan, L; Holick, MF; Pincus, SH; Smith, EL, 1988
)
0.27
"Serially cultivated keratinocytes of human and rat epidermis and esophagus were compared with respect to their sensitivity to toxic effects of 3-methylcholanthrene and ability to metabolize benzo(a)pyrene."( Polycyclic aromatic hydrocarbon toxicity and induction of metabolism in cultivated esophageal and epidermal keratinocytes.
Heimann, R; Rice, RH, 1983
)
0.27
" These results indicate that cholestatic biliary acids (LCS and TLCS) are toxic for biliary cells."( [Toxicity of cholestatic bile acids on intrahepatic biliary cells of the rat].
Diallo, A; Dumont, M; Erlinger, S; Faye, B; Poirel, O, 1994
)
0.29
" In this study, the toxic effects of mitomycin-C on cultured porcine keratocytes and endothelial cells were estimated by MTT, 3H-thymidine uptake and cellular counting assay methods."( Toxic effects of mitomycin-C on cultured corneal keratocytes and endothelial cells.
Chen, CW; Hong, SJ; Huang, HT; Lin, CP; Wu, KY, 1999
)
0.3
" We have previously shown that the haloacetic acids (HAs), dichloro (DCA), dibromo (DBA) and bromochloro (BCA) acetic acid are developmentally toxic in mouse whole embryo culture."( Developmental toxicity of mixtures: the water disinfection by-products dichloro-, dibromo- and bromochloro acetic acid in rat embryo culture.
Andrews, JE; Hunter, ES; Klinefelter, GR; Mole, LM; Nichols, HP; Schmid, JE, 2004
)
0.32
"The chemical composition of the leaching solution of CCK was determined by means of ultraviolet spectrometry, and the toxic effects of the solution was evaluated by skin sensitization test in rats, intracutaneous stimulation test in rabbits, acute systemic toxicity test in mice, and cytotoxicity test in L929 cells."( Toxicity evaluation of chicken calamus keratin conduit as a tissue-engineering scaffold biomaterial.
Chen, YH; Dong, WR; Qiu, XX; Xiao, YQ; Zhao, BL; Zou, ZZ, 2007
)
0.34
" In acute systemic toxic test, administration of the leaching solution in mice caused no death, organ dysfunction, cyanosis, tremor, severe peritoneal irritation, ptosis, or dyspnoea."( Toxicity evaluation of chicken calamus keratin conduit as a tissue-engineering scaffold biomaterial.
Chen, YH; Dong, WR; Qiu, XX; Xiao, YQ; Zhao, BL; Zou, ZZ, 2007
)
0.34
"CCK contained in the treated chicken calamus easily undergoes hydrolysis to release mainly some peptides which do not induce obvious toxic effects, suggesting the safe potential applications of CCK conduit as a tissue-engineering biomaterial."( Toxicity evaluation of chicken calamus keratin conduit as a tissue-engineering scaffold biomaterial.
Chen, YH; Dong, WR; Qiu, XX; Xiao, YQ; Zhao, BL; Zou, ZZ, 2007
)
0.34
" Our observations clearly demonstrate principally different mechanisms for acute and chronic toxic damage."( Transition between acute and chronic hepatotoxicity in mice is associated with impaired energy metabolism and induction of mitochondrial heme oxygenase-1.
Abuja, PM; Kratky, D; Lackner, C; Nikam, A; Patankar, JV; Schöck, E; Zatloukal, K, 2013
)
0.39
" Therefore, dental alloys containing In must be biologically evaluated for their safe use."( Cytotoxicity and terminal differentiation of human oral keratinocyte by indium ions from a silver-palladium-gold-indium dental alloy.
Kim, KM; Kim, KN; Lee, JH; Lee, SB; Om, JY; Seo, SH, 2015
)
0.42
" Suberanilohydroxamic acid (SAHA) however has been proposed to prevent corneal haze without any adverse effects."( Safety and efficacy of combination of suberoylamilide hydroxyamic acid and mitomycin C in reducing pro-fibrotic changes in human corneal epithelial cells.
Dadachanji, ZV; Das, D; Ghosh, A; Khamar, P; Krishna, L; Kumar, NR; Matalia, H; Mohan, RR; Murugeswari, P; Shetty, R; Subramani, M, 2021
)
0.62
" The Panel reviewed relevant data provided in this safety assessment and concluded that the 8 keratin-derived ingredients are safe in the present practices of use and concentration described in this safety assessment."( Safety Assessment of Keratin and Keratin-Derived Ingredients as Used in Cosmetics.
Belsito, DV; Bergfeld, WF; Burnett, CL; Gill, LJ; Heldreth, B; Hill, RA; Klaassen, CD; Liebler, DC; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" Method validation data are presented on three pharmacodynamic assays that will be utilised during this trial."( Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
Cummings, J; Dive, C; Durkin, J; LaCasse, E; Lefebvre, C; Ranson, M; St-Jean, M; Ward, TH, 2005
)
0.33

Compound-Compound Interactions

ExcerptReferenceRelevance
"Comparative study of treatment of keratocysts by enucleation, enucleation combined with cryotherapy or treatment with Carnoy's solution followed by enucleation: a preliminary report."( [Comparative study of treatment of keratocysts by enucleation, enucleation combined with cryotherapy or fixation of the cyst membrane with Carnoy's solution followed by enucleation: a preliminary report].
Jensen, J; Sindet-Pedersen, S; Tagesen, J, 1990
)
0.28
"We describe an in situ DNA nick end-labeling method that can be performed at the electron microscopic level and can also be combined with immunoelectron microscopy."( Electron microscopic in situ DNA nick end-labeling in combination with immunoelectron microscopy.
Iizuka, H; Ishida-Yamamoto, A; Nakane, H; Takahashi, H; Tanaka, H; Yamauchi, T, 1999
)
0.3
" This is the first reported case of diffuse pagetoid SCCIS combined with choriocarcinoma."( Diffuse pagetoid squamous cell carcinoma of the esophagus combined with choriocarcinoma and mucoepidermoid carcinoma: an autopsy case report.
Ishihara, A; Koono, M; Mori, T, 2002
)
0.31
" Despite its moderate specificity, when used in combination with epithelial marker AE1/AE3, it allowed to reliably distinguish hemangioblastoma from metastatic CCRCC."( Immunohistochemical markers to distinguish between hemangioblastoma and metastatic clear-cell renal cell carcinoma in the brain: utility of aquaporin1 combined with cytokeratin AE1/AE3 immunostaining.
Baumann, C; Bressenot, A; Joud, A; Klein, O; Marie, B; Montagne, K; Vignaud, JM; Weinbreck, N, 2008
)
0.35
" We used anti-CK alone or in combination with anti-EpCAM antibodies for CTC enrichment."( Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
Burgess, D; Burke, JF; Deng, G; Herrler, M; Krag, D; Manna, E, 2008
)
0.35
" Enrichment with anti-CK alone or combined with anti-EpCAM antibodies significantly enhances assay sensitivity."( Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
Burgess, D; Burke, JF; Deng, G; Herrler, M; Krag, D; Manna, E, 2008
)
0.35
" Therefore, we examined whether acute treatment with PEG IFN-beta would improve forelimb function alone or when combined with forced exercise (Ex)."( PEGylated interferon-beta modulates the acute inflammatory response and recovery when combined with forced exercise following cervical spinal contusion injury.
Baker, DP; Houle, JD; Miller, K; Sandrow-Feinberg, HR; Santi, L; Shumsky, JS; Zhukareva, V, 2010
)
0.36
"The first-ever application of high-frequency ultrasound combined with multiphoton tomography (MPT) and dermoscopy in a clinical trial is reported."( Clinical application of multiphoton tomography in combination with high-frequency ultrasound for evaluation of skin diseases.
Kaatz, M; Köhler, MJ; König, K; Scharenberg, R; Speicher, M, 2010
)
0.36
"Implants were inserted in mandibles in combination with ridge augmentation and extension of deficient buccal keratinized gingiva (BKT) with free gingival grafts (FGGs), in which the keratinized local gingiva (KLG) was transferred toward the lingual."( Clinical prospective study of a modified technique to extend the keratinized gingiva around implants in combination with ridge augmentation: one-year results.
Beuer, F; Edelhoff, D; Stangl, M; Stimmelmayr, M,
)
0.13
" Cox regression analyses showed that multimodal management combined with GKS was an independent positive prognostic factor for OS."( Multimodal treatments combined with gamma knife surgery for primary atypical teratoid/rhabdoid tumor of the central nervous system: a single-institute experience of 18 patients.
Ju, Y; Li, Q; Ren, YM; Wu, X; You, C; Zhang, YK, 2018
)
0.48
"Although AT/RTs are lethal cancer types, the OS of the disease was improved by using multimodal therapeutic strategies, including surgery, CMT, and RT, combined with GKS."( Multimodal treatments combined with gamma knife surgery for primary atypical teratoid/rhabdoid tumor of the central nervous system: a single-institute experience of 18 patients.
Ju, Y; Li, Q; Ren, YM; Wu, X; You, C; Zhang, YK, 2018
)
0.48
"To evaluate the effectiveness and safety of autologous fibroblasts combined with keratin gel for tear trough deformity rectification as injectable soft tissue filler."( Correction of Tear Trough Deformity Using Autologous Fibroblast Combined with Keratin: New Soft Tissue Filler.
Xing, W; Zhang, C; Zhang, J; Zhang, Q, 2019
)
0.51
"Adenoid basal carcinoma (ABC) is uncommon malignancy of the uterine cervix and it can be pure or combined with cervical intraepithelial lesions."( Adenoid basal carcinoma combined with invasive squamous cell carcinoma of uterine cervix: A case report of a 37-year-old woman and literature review.
Bektas, S; Salman, S; Yuksel, S, 2019
)
0.51
" TAP combined with CYFRA 21-1 and CA72-4 or with CYFRA 21-1, CA72-4 and squamous cell carcinoma antigen could further improve the sensitivity of lung cancer diagnosis and is suitable for lung cancer screening in both normal and high-risk populations."( Clinical application of serum tumor abnormal protein combined with tumor markers in lung cancer patients.
Dai, H; Dan, B; Tong, H; Zhu, M, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" The differential therapeutic effects in the epidermal and dermal skin compartments may be due to a reduced bioavailability of calcipotriol in the dermal compartment."( Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin.
Bahmer, FA; Baum, HP; Kerber, A; Müller, SM; Reichrath, J, 1997
)
0.3
"The bioavailability of RAL into the skin after topical RALGA was studied by HPLC, and its bioconversion to RA was analysed by measuring the enzyme activity of retinaldehyde dehydrogenase and the RA content in the epidermis and dermis."( Pharmacology of RALGA, a mixture of retinaldehyde and glycolic acid.
Carraux, P; Didierjean, L; Grand, D; Kasraee, B; Saurat, JH; Sorg, O; Tran, C, 2005
)
0.33
"05% alone; this indicates that the presence of GA favours the bioavailability and biotransformation of RAL into RA."( Pharmacology of RALGA, a mixture of retinaldehyde and glycolic acid.
Carraux, P; Didierjean, L; Grand, D; Kasraee, B; Saurat, JH; Sorg, O; Tran, C, 2005
)
0.33
"These observations indicate that the addition of an AHA such as GA to a retinoid such as RAL results in a better bioavailability of the retinoid, thus a higher delivery of RA, which potentiates the biological activities of the retinoid."( Pharmacology of RALGA, a mixture of retinaldehyde and glycolic acid.
Carraux, P; Didierjean, L; Grand, D; Kasraee, B; Saurat, JH; Sorg, O; Tran, C, 2005
)
0.33
" High antioxidant capacity, 100% bioavailability and a well-balanced amino acid composition was characteristic of the hydrolysis products."( [Enzymatic hydrolysis of keratin-containing stock for obtaining protein hydrolysates].
Eremeev, NL; Ismailova, DIu; Keruchen'ko, ID; Khotchenkov, VP; Koroleva, OV; Nikolaev, IV; Satrutdinov, AD; Sinitsyn, AP; Stepanova, EV; Tsurikova, NV; Volik, VG; Zinov'ev, SV,
)
0.13
" This was evaluated in anesthetised and conscious rats and mini-pigs, to measure the relative bioavailability of propofol following buccal administration, but also partly to evaluate the animal models used for this investigation."( Buccal absorption of propofol when dosed in 1-perfluorobutylpentane to anaesthetised and conscious Wistar rats and Göttingen mini-pigs.
Holm, P; Holm, R; Quintel, M; Theisinger, S; Thiel, M; Tsagogiorgas, C, 2013
)
0.39
" Absorption rate experiments showed a longer lag time for intact SC than for delipidized SC or SC lipid, suggesting that the water domain may delay chemical binding to protein and lipid domains, and may be a factor in the resistance of many chemicals to current decontamination methods."( Proposed human stratum corneum water domain in chemical absorption.
Hui, X; Jung, EC; Maibach, H; Zhu, H, 2016
)
0.43
" In conclusion, these data support the use of SPP to enhance the skin penetration of poorly absorbed compounds even in the case of macromolecules as polysaccharides."( Skin Penetrating Peptide as a Tool to Enhance the Permeation of Heparin through Human Epidermis.
Cilurzo, F; Corsini, E; Franzè, S; Gennari, CG; Minghetti, P; Montanari, L; Pellegrino, S; Vistoli, G, 2016
)
0.43
" Compared with the PLGA/wool keratin composite membrane prepared by traditional electrospinning, the composite membranes prepared by emulsion electrospinning had a higher water absorption rate and superior hydrophilicity."( Controlled release of bFGF loaded into electrospun core-shell fibrous membranes for use in guided tissue regeneration.
Cai, Z; Gao, T; Liu, J; Ma, H; Wang, K; Zhang, H; Zhang, R; Zhang, W, 2020
)
0.56
" Moreover, comparative penetration experiments of a reference formulation with and without added keratin or keratin-adherent permethrin showed that keratin causes a steal effect for permethrin, leading to a relevant reduction in cutaneous bioavailability in the target compartment."( Permethrin Steal Effect by Unmasked Corneocytic Keratin in Topical Therapy of Scabies.
Chuttke, J; Eichner, A; Fritz, C; Scholz, L; Wohlrab, J, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" It was possible to lower the dosage of each and still achieve remarkable therapeutic responses."( Simultaneous intermittent bleomycin and radiological treatment of laryngeal cancer.
Berdal, P; Iversen, OH; Weyde, R, 1975
)
0.25
" A clear dose-response relationship was found in the promotion of epithelial keratinization by MNNG."( Promotion of epithelial keratinization by N-methyl-N'-nitro-N-nitrosoguanidine in rat forestomach in organ culture.
Fukamachi, H; Takayama, S, 1979
)
0.26
" Vitamin A and its analogs prevented the keratinization in 2 out of 3 lines at dosage over 1 micrograms/ml, but other drugs such as vitamin C, E, and K, steroid hormones, cyclic AMP, polyamines, polyanions, and dimethyl sulfoxide were ineffective for preventing keratinization."( Keratinization of transformed epithelial cells of the rat urinary bladder: its quantification and effect of various drugs.
Hashimoto, Y; Kawamura, H, 1979
)
0.26
" Testing of the pluripotency of the ES-like cells demonstrated that 1) among four lines of genotype XX, and X was late-replicating in three; both Xs were active in about one-third of cells of line MES8, and analysis of glucose-6-phosphate dehydrogenase revealed no dosage compensation for the X-linked gene; 2) when cultured in suspension, the majority of lines were capable of forming "simple" embryoid bodies (EB), and two only showed the capacity for forming "cystic" multilayer EBs."( Isolation and cultivation of blastocyst-derived stem cell lines from American mink (Mustela vison).
Andreeva, LE; Bayborodin, SI; Golubitsa, AN; Maximovsky, LP; McWhir, J; Pack, SD; Shilov, AG; Sukoyan, MA; Vatolin, SY; Zhelezova, AI, 1992
)
0.28
" In this study, we compared, in dose-response experiments, the biologic activities of retinoic acid and CD271, a substance unable to bind to CRABP, but able to bind to nuclear retinoic acid receptors (RAR)."( Control of epidermal differentiation by a retinoid analogue unable to bind to cytosolic retinoic acid-binding proteins (CRABP).
Asselineau, D; Cavey, MT; Darmon, M; Shroot, B, 1992
)
0.28
" Moreover, liarozole possessed antikeratinizing activity: when dosed subchronically (5-20 mg/kg, once daily for 3 days) to ovariectomized rats, the compound reversed the vaginal keratinization induced in these animals by estrogenic stimulation."( Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo.
Borghgraef, P; Coene, MC; Cools, W; Goossens, J; Janssen, PA; Stoppie, P; Van Nyen, G; Van Wauwe, J, 1992
)
0.28
" Dose-response studies with several mutagens indicated that the number of foci increased with concentration to the point where excessive cytotoxicity developed."( Development of an in vitro model to study carcinogen-induced neoplastic progression of initiated mouse epidermal cells.
Glick, A; Greenhalgh, D; Hennings, H; Morgan, D; Welty, D; Yuspa, SH, 1992
)
0.28
" The genetic basis of this variation was confirmed by both quantitative gene dosage dependence and the transmission of the variants as Mendelian traits in two families."( Allele frequencies and segregation of human polymorphic keratins K4 and K5.
Mischke, D; Wild, AG; Wille, G, 1990
)
0.28
" The area under the plasma concentration-time curve of salicylic acid following the administration of salicylic acid to the oral mucosa with a film dosage form and the thickness of stratum corneum of each site were in inverse proportion to each other, suggesting that the stratum corneum layer represents the principle barrier to drug absorption."( Regional variation in oral mucosal drug absorption: permeability and degree of keratinization in hamster oral cavity.
Kimura, T; Kurosaki, Y; Nakayama, T; Nishimura, H; Takatori, T, 1991
)
0.28
" Differences among cell types in the kinetics, frequency, and gene dosage requirements for gene expression provide clues to the underlying regulatory mechanisms."( Plasticity of the differentiated state.
Blau, HM; Chiu, CP; Hardeman, EC; Miller, SC; Pavlath, GK; Silberstein, L; Webster, C; Webster, SG, 1985
)
0.27
" After two-step HPLC separation, a linear stimulatory dose-response curve for colony stimulation was obtained for GM- and Eo-type colony growth in methylcellulose."( Granulocyte colony stimulating activity derived from human keratinocytes.
Denburg, JA; Sauder, DN, 1986
)
0.27
" In a dose-response study with minoxidil, the maximal effect of the drug was seen at doses from 6 to 12 micrograms/ml; however, activity could be detected at doses below 1 microgram/ml."( Effect of minoxidil on pre- and postconfluent keratinocytes.
Baden, HP; Kubilus, J; Kvedar, JC, 1987
)
0.27
" Time-course and dose-response studies of CB treatment showed lattice formation to follow disruption of stress fibers and the concentration of actin into distinct patches that marked the location of lattice foci."( Cytochalasin B-induced redistribution of cytokeratin filaments in PtK1 cells.
Mullins, JM; Wolf, KM, 1987
)
0.27
" When DNA synthesis and involucrin expression were plotted against contact area, classic dose-response curves were obtained."( Cell shape controls terminal differentiation of human epidermal keratinocytes.
Jordan, PW; O'Neill, CH; Watt, FM, 1988
)
0.27
" The dose-response curve to I was virtually identical for stimulating cell proliferation and for reducing the frequency of actin-immunoreactive cells (ED50 in the range of 30 ng/ml), suggesting that the two processes were controlled by the same initial I-receptor interaction."( Growth factor control of myoepithelial-cell differentiation in cultures of human mammary gland.
Petersen, OW; van Deurs, B, 1988
)
0.27
" In addition, the time course, maximal efficiency, and effect of gene dosage on the expression of muscle gene products were similar for heterokaryons containing fetal and adult fibroblasts but distinct for heterokaryons containing keratinocytes."( In vivo aging of human fibroblasts does not alter nuclear plasticity in heterokaryons.
Blau, HM; Chiu, CP; Pavlath, GK, 1989
)
0.28
" The end points used to assess toxicity were acid phosphatase (AP) activity after 4 h of dosing and neutral red (NR) uptake and kenacid blue (KB) staining after 3 d to assess cell viability and number."( Irritancy testing in cultured keratinocytes.
Benford, DJ; Gajjar, L,
)
0.13
" Following the oral dosing of deficient animals (T12) with 350 micrograms retinyl palmitate, all such changes were reversed within 6 days in the trachea and within 10 days in the submaxillary and sublingual glands."( Morphologic alterations in the trachea and the salivary gland following the induction of rapid synchronous vitamin A deficiency in rats.
Anzano, MA; Lamb, AJ; Olson, JA, 1980
)
0.26
"Ten patients with disorders of keratinization were treated with oral isotretinoin (13-cis-retinoic acid) on an investigational protocol to test the efficacy, safety, and optimal dosage schedule for using the drug in these rare disorders."( Elevation of serum triglyceride levels from oral isotretinoin in disorders of keratinization.
Jorgensen, H; Katz, RA; Nigra, TP, 1980
)
0.26
"The chemistry, pharmacology, pharmacokinetics, clinical use, adverse effects, dosage and administration, and FDA-approved indications of isotretinoin, a new agent used for treating acne, are reviewed."( Isotretinoin: new therapy for severe acne.
McEvoy, GK; Perry, MD,
)
0.13
" Mean utriculus diameters in whole mount epidermis were determined and dose-response relationships were constructed after topical or oral administration of test retinoids."( Topical and systemic effects of retinoids on horn-filled utriculus size in the rhino mouse. A model to quantify "antikeratinizing" effects of retinoids.
Bhatia, MC; Capetola, RJ; Mezick, JA, 1984
)
0.27
"Aurokeratinate (Auro-Detoxin) was administered intramuscularly to patients with chronic rheumatoid arthritis, using two different dosage schedules and measuring serum gold concentration."( [Pharmacokinetics of gold after administration of aurokeratinate (author's transl)].
Herrlinger, JD; Seiler, KU, 1980
)
0.26
"A CK immunohistochemical study was carried out on histologic sections from hepatocellular carcinomas (HCCs) and preneoplastic lesions from 118 monkeys chronically dosed with diethylnitrosamine (DEN), using mAbs to CK 8, CK 18, CK 7, and CK 19."( Cytokeratin patterns of liver carcinomas induced by diethylnitrosamine in monkeys.
Bocsi, J; Lapis, K; Sarosi, I; Thorgeirsson, UP, 1995
)
0.29
" The reliability of the immunoradiometric assay was demonstrated by the linear relationship between CYFRA 21-1 measurement and dilution of the serum, the reproducibility of the dosage in intraassay and interassay, and the high sensitivity of the method in discriminating low CYFRA 21-1 concentrations."( Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.
Daurès, JP; Daver, A; Grenier, J; Michel, FB; Pujol, H; Pujol, JL, 1993
)
0.29
" Information collected included demographic data, dosage of etretinate taken, response and side effects, clinical follow-up, and relapse."( Etretinate therapy for psoriasis and other keratinizing disorders: a 10-year retrospective study in Singapore.
Goh, CL; Shahidullah, M; Tham, SN, 1993
)
0.29
"Exposure of corneal keratocytes and epithelial cells to either interleukin-1 alpha or TNF-alpha stimulated IL-8 mRNA synthesis and IL-8 production in a dose-response fashion."( IL-8 gene expression in cultures of human corneal epithelial cells and keratocytes.
Cubitt, CL; Lausch, RN; Monteiro, CA; Oakes, JE; Tang, Q, 1993
)
0.29
" In an ongoing carcinogenesis study, 34 out of 40 monkeys dosed with IQ have developed malignant liver tumors."( Liver tumors and possible preneoplastic lesions, induced by a food-derived heterocyclic amine in cynomolgus monkeys; a study of histology and cytokeratin expression.
Adamson, RH; Gomez, DE; Lindsay, CK; Sinha, CC; Thorgeirsson, UP, 1996
)
0.29
" Seventy-five percent of hemizygous and 100% of homozygous transgenic males developed prostate tumors, suggesting a T Ag dosage effect."( Prostate cancer progression, metastasis, and gene expression in transgenic mice.
Altman, NH; Deftos, LJ; Mehta, PP; Perez-Stable, C; Roos, BA, 1997
)
0.3
" Finally, a dose-response study showed that the de novo appearance of K4 can be utilized as a sensitive test for retinoid bioactivity in epidermis in vivo."( Keratin 4 upregulation by retinoic acid in vivo: a sensitive marker for retinoid bioactivity in human epidermis.
Törmä, H; Vahlquist, A; Virtanen, M, 2000
)
0.31
" The dose-response relationship for HRPE cells to HGF/SF was investigated by a cell migration assay and the specificity of this response evaluated by a neutralization experiment."( Active scatter factor (HGF/SF) in proliferative vitreoretinal disease.
Briggs, MC; Grierson, I; Hiscott, P; Hunt, JA, 2000
)
0.31
" To examine whether a pre-natal exposure to a potentially non-teratogenic dosage of all-trans-RA had any effect on vibrissal follicle development, the histologic and immunohistochemical responses to RA during its morphogenesis in NMRI mouse were investigated."( Effects of retinoic acid exposure in utero on mouse vibrissal follicle development.
Escudero-Diez, A; García-Fernández, RA; García-Iglesias, MJ; Pérez-Martínez, C, 2000
)
0.31
" experimental newborn rats were given clomphene citrate subcutaneously in a dosage of 100 mg/kg/day for five days."( Effects of clomiphene citrate on neonatal rat skin.
Deveci, E; Inalöz, HS; Inalöz, SS; Unal, B, 2000
)
0.31
" 1 1/2 y], on FN [2 Gy/day up to a total dosage of 20/40/60 Gy (x-rays)], on RF (inside vs."( Dose-response relationships on the expression profile of cytokeratins and vimentin in rat submandibular glands following fractionated irradiation.
Bartel-Friedrich, S; Friedrich, RE; Holzhausen, HJ; Lautenschläger, C; Moll, R,
)
0.13
" The effects of irradiation vary according to the irradiation field (RF), the dosage and the strain of rat."( Cytokeratin expression in carcinomas of irradiated rats.
Arps, H; Bartel-Friedrich, S; Friedrich, RE; Holzhausen, HJ,
)
0.13
" Pregnant mice were dosed orally with 5 micro g TCDD/kg or vehicle on GD 13, and their pups were fostered at birth to dams of the same treatment or cross-fostered to dams of the opposite treatment."( Critical windows of vulnerability for effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on prostate and seminal vesicle development in C57BL/6 mice.
Lin, TM; Moore, RW; Peterson, RE; Simanainen, U, 2002
)
0.31
" These results in adult mice indicate BCA disrupted differentiation of spermatids during dosing and the first 10 days of mating, and are consistent with the spermatid retention and atypical residual bodies observed in animals exposed to 72 and 216 mg/kg BCA."( Reproductive and genomic effects in testes from mice exposed to the water disinfectant byproduct bromochloroacetic acid.
Dix, DJ; Luft, JC; Ren, H; Rockett, JC; Schmid, JE; Tully, DB; Wood, CR,
)
0.35
"PAX6 heterozygosity (PAX6(+/-)) causes aniridia and aniridia-related keratopathy (ARK) in humans, but the pathway from gene dosage deficiency to clinical disease has not been fully characterized."( Cytoskeletal and cell adhesion defects in wounded and Pax6+/- corneal epithelia.
Collinson, JM; Lowes, C; Ou, J, 2010
)
0.36
" Following 3 months of oral dosing with vehicle, or sitagliptin at doses 3- to 19-fold above the clinically therapeutic plasma concentration, which increased active plasma glucagon-like peptide-1 levels up to approximately 3-fold, or following 3 months of oral dosing with metformin, a non-incretin-based reference T2DM treatment, the pancreas of male ZDF rats was evaluated using qualitative and quantitative histopathology techniques."( Characterization of the exocrine pancreas in the male Zucker diabetic fatty rat model of type 2 diabetes mellitus following 3 months of treatment with sitagliptin.
Cunningham, C; Dey, M; Forest, T; Frederick, C; Holder, D; Prahalada, S; Smith, A; Yao, X, 2014
)
0.4
" The adsorption capacity increased with increasing the initial dye concentration and pH, while it decreased with increasing the adsorbent dosage and temperature, indicating an exothermic process."( Study of Methylene Blue adsorption on keratin nanofibrous membranes.
Aluigi, A; Jannoke, L; Rombaldoni, F; Tonetti, C, 2014
)
0.4
" After reduced dosing of tacrolimus and mycophenolate mofetil, 2 limbal tumors occurred in the recipient."( Transmission of Donor-Derived Breast Carcinoma as a Recurrent Mass in a Keratolimbal Allograft.
Chamberlain, W; Dunlap, J; Miller, AK; Wilson, DJ; Young, JW, 2017
)
0.46
"Nanotechnology-based drug delivery systems have been widely used for oral and systemic dosage forms delivery depending on the mucoadhesive interaction, and keratin has been applied for biomedical applications and drug delivery."( Development of keratin nanoparticles for controlled gastric mucoadhesion and drug release.
Chen, X; Cheng, Z; Gao, F; Guo, T; Hao, S; Ji, J; Li, W; Wang, B; Zhai, D, 2018
)
0.48
" Identifying oncogenic drivers that work primarily through dosage changes is a current challenge."( Profound Tissue Specificity in Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns.
Bernardi, RJ; Chen, T; Davoli, T; Elledge, SJ; Leng, Y; Li, MZ; Li, Y; Liang, AC; Martin, TD; Naxerova, K; Sack, LM; Scorsone, KA; Westbrook, TF; Wong, KK; Wooten, EC; Xu, Q, 2018
)
0.48
" The in vitro experiments revealed the enhanced antitumor efficacy of the C-PK/- SS-Hy-D NPs than the free DOX at a higher dosage of >10 μg/mL."( One-Pot Synthesis of Chicken-Feather-Keratin-Based Prodrug Nanoparticles with High Drug Content for Tumor Intracellular DOX Delivery.
Liu, P; Zhang, H, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
2-bromocarboxylic acidAny carboxylic acid in which the carbon bearing the carboxy group is substituted by a bromine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency24.60900.006038.004119,952.5996AID1159521
AR proteinHomo sapiens (human)Potency44.66840.000221.22318,912.5098AID588516
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency15.52720.001022.650876.6163AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency59.22950.003041.611522,387.1992AID1159552; AID1159555
thyroid stimulating hormone receptorHomo sapiens (human)Potency27.61180.001628.015177.1139AID1259385
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency14.63700.000627.21521,122.0200AID651741; AID743202; AID743219
Cellular tumor antigen p53Homo sapiens (human)Potency0.87320.002319.595674.0614AID651631
Nuclear receptor ROR-gammaHomo sapiens (human)Potency29.84930.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (134)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID384212Mutagenic activity in Salmonella Typhimurium TA100 assessed as logarithm of his+ revertant number increasing activity by amens test2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Halogenated derivatives QSAR model using spectral moments to predict haloacetic acids (HAA) mutagenicity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20,866)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905840 (27.99)18.7374
1990's5553 (26.61)18.2507
2000's5737 (27.49)29.6817
2010's2933 (14.06)24.3611
2020's803 (3.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.89 (24.57)
Research Supply Index10.02 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index39.83 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials258 (1.16%)5.53%
Reviews1,478 (6.65%)6.00%
Case Studies3,049 (13.72%)4.05%
Observational10 (0.05%)0.25%
Other17,424 (78.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]